normal tissue. Subsequently, the development of vascular-and tissue damage after a therapeutic light dose (760 nm, 600 J cm-2) was observed. Fifteen minutes post injection (p.i.), the fluorescence of BCA in the tumour reached a plateau value of 2.5 times the fluorescence in the normal tissue. From 1 h post injection the tumour fluorescence diminished gradually; after 24 h, the tumour fluorescence signal did not exceed that of the normal tissue. Following photodynamic therapy (PDT), 24 h p.i., complete vascular stasis was observed 2 h post treatment in the tumour only, with subsequent recovery. The presence of viable tumour cells following PDT was assessed by histology and re-transplantation of treated tumour tissue from the chamber into the flank immediately or 7 days after treatment. In both cases tumour regrowth was observed. BCA-PDT (20mg kg-', 760 nm, 100 J cm-2) h after BCA administration, an interval which gives the optimal differential between tumour and normal tissue, was sufficient to prevent tumour regrowth. However, this only occurred when re-transplantation was performed 7 days after PDT. During PDT, I h p.i., vascular damage in tumour and normal tissue was considerable. Complete vascular shut-down was observed in the tumour 2 h after therapy and in the surrounding tissues at 24 h. Circulation damage was associated with vascular spasm and occlusion probably due to thrombi formation. Oedema was notable, especially following PDT with 600Jcm-2 at 24h p.i.
Tumour destruction by photodynamic therapy is achieved through retention of photosensitising compounds in tissue after injection and the subsequent activation of these compounds by irradiation with light of appropriate wavelength and dose. The photosensitiser currently evaluated in phase III clinical trials is Photofrin®9, a derivative of hematoporphyrin, enriched in the photodynamically active fraction. However, Photofrin'9 has a number of drawbacks. In particular it induces skin photosensitivity for periods up to 6 weeks and is chemically ill defined. These drawbacks have prompted an intensive worldwide search for new photosensitisers (Kessel, 1990) . A good candidate for 'second generation' photosensitiser is bacteriochlorin a (BCA). BCA is a derivative of bacteriochlorophyll a and a potent photosensitiser both in vitro and in vivo (Schuitmaker et al., 1990) . Its lipophilic nature enhances the cellular uptake of the dye (Richter et al., 1991) . Effects on mitochondria ex vivo resulting from therapy (Schuitmaker et al., 1991) and in vivo tumour fluorescence have been demonstrated (Schuitmaker et al., 1992) . This photosensitiser has a major absorption peak at 760 nm, a wavelength where tissue penetration is optimal . With this photosensitiser the penetration depth of the therapeutic light and thus the treated volume may be maximised.
The exact mechanism of tumour necrosis resulting from PDT is still not fully elucidated. Originally it was thought that PDT was effective only through the selective localisation of the photosensitiser in the tumour cells. The tumour cells were subsequently killed by singlet oxygen, produced when the dye was irradiated with light of an appropriate wavelength. However, there exists accumulating evidence that an important and immediate effect of PDT is on the vasculature of the tumour and surrounding tissues, depending on the sensitiser used (Henderson & Dougherty, 1992) . This results in a decreasing blood flow and eventually vascular stasis (Star et al., 1986; Franken et al., 1988; Schuitmaker et al., 1990) . The fluorescence of BCA is of practical interest in PDT as it may be a sensitive non-contact way of detecting otherwise occult cancers and make them accessible for regular biopsy, eventually combining potential tumour-tissue identification and photodynamic therapy (Lam et al., 1990) .
In the present paper we report on the fluorescence kinetics of BCA and on BCA-PDT induced damage to tumour and normal tissue circulation in vivo.
Materials and methods
Preparation of BCA Bacteriochlorophyll a was obtained by extraction from the photosynthetic anaerobic bacterium Rhodospirillum rubrum and purified according to the method of Omata et al. (1983) .
The purity of the pigment was checked by thin-layer chromatography (TLC). Using an eluent of 93% methanol and 7% phosphate buffer (pH 7, 10 mM), the bacteriochlorophyll a yielded a single blue spot (relative mobility approximately 0.5) on Machery-Nagel Nano-Sil C,8-100 TLC plates (Diiren, Germany). Bacteriochlorophyllin a was obtained by saponifying bacteriochlorophyll a as described by Oster et al. (1964) (Reinhold et al., 1979) Photodynamic therapy Light of 760 nm wavelength was obtained from a dye laser (Spectra Physics 375B, with Styryl 8), pumped by an argonion (Spectra Physics 171) laser. Light, at a power density of 100 mW/cm 2, was delivered to the chamber via an optical fibre and a lens system with diaphragm yielding a uniform beam of 10 mm diameter covering the entire window of the chamber (9 mm in diameter). Two groups of six animals were treated. In the first group fluorescence was studied and PDT was performed 24 h p.i. of BCA, with a light dose of 600 J cm-2. In the second group PDT was performed 1 h p.i., with a light dose of 100 J cm-2. animals from the group of six was determined during a 7 day follow-up period. Then, the tumour and a margin of normal tissue (or the necrotic remains) was removed from the chamber and retransplanted into the flank of the same animal. In two animals from each group the tumour and a margin of normal tissue was retransplanted 2 h after therapy to see whether enough damage was inflicted to prevent tumour regrowth. Finally one chamber from each group was prepared for histology. In the second series of six animals a therapeutic light dose of 100 J cm-2 was delivered at a much shorter interval of 60 min p.i. Apart from that a similar protocol was followed. All sensitised animals were kept under reduced light conditions (<30 jiW cm-2) with a 12/12 h day/ night cycle. Note that the fluorescence of the normal tissue hardly changes during the observation period. When expressed as ratios relative to normal tissue, tumour tissue fluorescence increases to a value of 2.5 (interval of 15 min). This level is maintained up to 60 min p.i., but at 120 min it has declined to a ratio of 1.6. At 24 h p.i., the tumour fluorescence ratio has dropped below 1. On average, the fluorescence of the normal tissue then slightly exceeds that of tumour and vasculature. Blood vessel ratios peak immediately post injection and at 5 min p.i. a level of 2.5 times the fluorescence of the normal tissue is recorded. Gradually this level decreases to become indistinguishable from the normal tissue (a ratio of 1) 2 h p.i.
The circulation damage scores during and after a therapeutic treatment with 600 J cm-2 at 24 h p.i. are shown in Figure 3a . Tumour vasculature appears to be damaged to a larger extent than blood vessels in the normal tissue. Only at 2 h after therapy a maximum score of 8 (no circulation observed) is reached for the tumour vasculature. Figure 3a also shows that, following the protocol with a 24 h interval, the circulation in tumour and normal tissue recovers to a score of about 3-4 within 6-7 days. Usually the larger vessels recover or existing smaller branches increase in diameter. The damaged capillary bed is replaced by new capillaries. Note that during the 100 min of illumination, vascular damage developed very slowly reaching a circulation damage score of 3 (normal tissue) -5 (tumour tissue) at the end of this period. Histology performed 2 h after the treatment light dose demonstrated the presence of viable tumour cells. With this treatment regime, tumour regrowth after reimplantation following therapy was never prevented, not immediately post treatment nor after the 7 day follow up period.
In the second series of PDT treatments an interval of 1 h between i.v. administration of BCA and therapeutic illumination was chosen. This decision was based on the results of the fluorescence kinetics study (see Figure 2) . Furthermore the light dose was reduced from 600 J cm-2 to 100 J cm-' in view of the higher photosensitiser concentration present at this interval. The vascular damage scores of these experi- ments are presented in Figure 3b . tually resulted in complete vascular stasis and prevention of tumour tissue regrowth upon reimplantation at the end of a 7 day follow-up period.
In the case of PDT using hematoporphyrin derivate (HpD) or Photofrin@ the most common interval between administration of the photosensitiser and illumination of the tumour is 24-48 h. In a first attempt to realise a therapeutic protocol, an interval of 24 h between i.v. administration of BCA and the therapeutic illumination was chosen. Furthermore a BCA dose of 20 mg kg-' was selected based on previous experience (Schuitmaker et al., 1990) . However, as Figure 3a demonstrates, using this protocol and despite the relatively high light dose that was applied, it was not possible to achieve complete and irreversible vascular stasis in the observation chamber model and tumour regrowth always occurred. This observation coincides with the lack of selectivity and reduced fluorescence at 24 h p.i. (Figure 2) . Therefore, in the second series of experiments the tumour was treated 1 h after administration of the dye. The choice for this 1 h interval was entirely based on the preceding in vivo fluorescence kinetics study (see Table I ). This study showed that in the window chamber model, tumour selec- iiii iiiii
iiie iiiii i tivity up to 2.5 times the fluorescence signal of the normal tissue can be achieved, during 15 to 60 min p.i. At 60 min p.i. the fluorescence signal ratio of the vessels has decreased by approximately 40% of the highest value whereas this ratio in the tumour had dropped by less than 5% of its highest value. At 24 h p.i. tumour and blood vessel ratios become indistinguishable from the normal tissue, similar to what is observed with HpD in the same model (van Leengoed et al., 1990) . A six fold reduction of the light dose to 100 J cm-2 (100 mW cm-2) was chosen as a higher overall concentration of the photosensitiser was expected. This light dose resulted in complete and irreparable vascular stasis in the observation chamber. Furthermore, tumour regrowth was prevented in those cases where the tumour was left in situ during the 7-day follow up period and was subsequently retransplanted in the flank of the same animal.
The fact that 24 h appears not to be the optimum interval has also been noted for other photosensitisers, e.g. chlorins (Gomer, 1991) and bacteriochlorophyll a (Henderson et al., 1991) . As is shown above, the fluorescence kinetics in vivo can be used to determine a 'therapeutic window' i.e. a suitable time interval between dye administration and PDT. This is different from HpD-PDT, where in this observation chamber model, 2 h p.i., tumour fluorescence could be discriminated from normal tissue in only 40-50% of the cases (van Leengoed et al., 1990) . In this model complete necrosis required a light dose of 160 J cm-2 at 630 nm applied 24 h p.i. of 15 mg kg-' HpD (Star et al., 1986) . Although vascular effects are not the primary target of the therapy, the resulting sterilisation of the tumour-bed will prevent nutritional resupply to still viable tumour cells through diffusion or angiogenesis (Fingar & Henderson, 1987) thereby enhancing the effect of the therapy.
The circulation damage scores (Figure 3a ) of the PDT treatment at 24 h p.i. show a differential effect on the vasculature of the tumour tissue and the normal tissue. This might be partly explained by the fact that in this model, tumour tissue only contains capillaries whereas the normal tissue contains capillaries and larger vessels. A maximum damage score is reached only 2 h after therapy and only in the tumour; from then on the circulation of tumour and normal tissue recovers. As a result, PDT treatment 24 h p.i. of BCA rendered no 'cures'. At this interval no fluorescence could be detected in the tumour nor in vessels which in this case could indicate that the BCA concentration in the vessels, tumour and normal tissue was too low to be effective. When a 24 h interval between administration and therapy was studied, the blood supply to the tumour was maintained during an illumination time of at least 60 min (360 J cMu2).
This delayed vascular shut down might increase the direct tumour cell kill as this is dependent on the availability of oxygen. Nevertheless, enough tumour cells apparently escaped therapy, causing tumour regrowth in all cases. With only 1 h between administration and therapy, where BCA fluorescence was still detectable in the vasculature, 30 J cm-2 ( = 5 min of illumination) resulted in higher circulation damage scores than 600 J cM-2 of light at the 24 h interval. Five minutes after the start of illumination, vascular spasms, circulating and occluding thrombi were observed. These direct vascular effects have also been reported during porphyrin based PDT (Star et al., 1986; Reed et al., 1988) .
Following 100 J cM-2 of light applied 1 h p.i., the tumourand normal tissue damage was sufficient to prevent tumour regrowth following retransplantation at day 7. Two hours post therapy re-transplantation yielded regrowth of the tumour, demonstrating the presence of viable tumour cells at this time. This observation agrees with the findings of Henderson (1992) that cells removed immediately after PDT can be viable in vitro, and stresses the role of tumour-bed damage in determining the final outcome of photodynamic therapy. Histology performed 2 h post therapy revealed that individual tumour cells survived following PDT at 1 h as well as at 24 h p.i. Probably the interval at which histology was performed was not optimal with respect to predicting the effectiveness of the therapy since one of the treatment schemes was effective in preventing tumour regrowth.
Summarising, BCA is useful, not only to induce tumour necrosis in PDT but for tumour detection by fluorescence as well. It induces selective fluorescence from 5 to 120 min p.i. in mammary tumours in the present model. In this respect and in this model, BCA is a much better tumour localiser than HpD. In vivo fluorescence of BCA can be used to determine a suitable time interval between i.v. administration of the dye and the subsequent therapeutic illumination of tumour tissue. The therapeutic ratio of the dye can be increased by making use of the photobleaching properties of the dye. In vitro, a 50% decrease of the absorption of 760 nm is observed after 86 J cM-2 (unpublished data J.J. S.). At the end of the therapeutic treatment viable tumour cells must be present as immediate retransplantation always results in tumour regrowth. Vascular damage appears to be a prerequisite to obtain tumour control with BCA. Determining the optimum sensitiser dose and interval between drug administration and therapy should be the subject of further study.
